Mesenchymal stem/stromal cells (MSC) transfected with stromal derived factor 1 (SDF-1) for therapeutic neovascularization: enhancement of cell recruitment and entrapment.
Recruited bone marrow-derived circulating cells (RBCCs) play a key role in therapeutic neovascularization. Several important steps take place during this process, which include mobilization, migration, recruitment, adhesion and invasion, entrapment, differentiation, as well as paracrine functions. Recent study indicated that recruitment and entrapment of RBCCs are vital steps in vascular endothelial growth factor (VEGF)-induced angiogenesis. This entrapment is modulated by another important chemokine: stromal derived factor 1 (SDF-1). We reason that the enhancement of entrapment might be a novel target for therapeutic neovascularization. Therefore we hypothesize that mesenchymal stem/stromal cells that secrete VEGF in situ could be transfected with SDF-1 (MSC(SDF-1)). Their combination could augment mobilization, recruitment, survival, and above all the entrapment of RBCCs, all of which might greatly augment the angiogenesis pathway. For these reasons, we further hypothesize that MSC(SDF-1) might become a next generation cell/chemokine therapy for therapeutic neovascularization.
Zhou
Bin
B
Department of Cardiology, Children's Hospital Boston, Harvard Medical School, Enders 13, 300 Longwood Avenue, Boston, MA 02115, USA. bzhou@enders.tch.harvard.edu
Han
Zhong Chao
ZC
Poon
Man-Chiu
MC
Pu
William
W
D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000235:genetics* / Q000502:physiology; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000502:physiology*; D008954:Models, Biological; D018919:Neovascularization, Physiologic; D017154:Stromal Cells / Q000166:cytology / Q000502:physiology*; D014162:Transfection / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D019743:Chemokines, CXC; D042461:Vascular Endothelial Growth Factor A